+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Acid Sphingomyelinase Deficiency (ASMD) - Epidemiology Forecast to 2028

  • ID: 4845143
  • Report
  • September 2019
  • Region: Global
  • 60 pages
  • DelveInsight
1 of 2
‘Acid sphingomyelinase deficiency (ASMD) - Epidemiology Forecast to 2028' report delivers an in-depth understanding of the disease, historical & forecasted epidemiology of Acid sphingomyelinase deficiency in the 10 Emerging Markets (EM) ,i.e., Turkey, Russia, Saudi Arabia, UAE, Mexico, Colombia, Brazil, Argentina, China and Taiwan.

Geography Covered
  • Asia (China and Taiwan)
  • Middle East (Turkey, Saudi Arabia, UAE)
  • Eastern Europe (Russia)
  • LATAM (Brazil, Mexico, Colombia and Argentina)
Study Period:2017-2028

Acid sphingomyelinase deficiency Disease Understanding

Acid sphingomyelinase deficiency (ASMD) is a rare progressive genetic disorder that results from a deficiency of the enzyme acid sphingomyelinase, which is required to break down (metabolize) a fatty substance (lipid) called sphingomyelin and inherited in an autosomal recessive pattern. Acid sphingomyelinase, E.C. 3.1.4.12, (ASM) is a lysosomal phosphodiesterase enzyme that hydrolyzes sphingomyelin, a phospholipid storage substance found in the brain, liver, lungs, spleen and lymph nodes, to ceramide and phosphorylcholine. It is also known as Niemann-Pick disease.

Acid sphingomyelinase deficiency Epidemiology

The Acid sphingomyelinase deficiency (ASMD) epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 10 emerging countries. The epidemiology data for Acid sphingomyelinase deficiency are studied through all possible division to give a better understanding about the Disease scenario in 10EM. It also helps to recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.

Acid sphingomyelinase deficiency Epidemiology Segmentation
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (total prevalent population, total diagnosed cases of Acid sphingomyelinase deficiency, diagnosed cases of ASMD by clinical phenotype, and diagnosed cases of ASMD based on clinical manifestations) scenario of Acid sphingomyelinase deficiency (ASMD) in the 10EM covering Turkey, Russia, Saudi Arabia, UAE, Mexico, Colombia, Brazil, Argentina, China and Taiwan) from 2017-2028.

The Report also provides the epidemiology trends observed in the 10EM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.

According to this report, the total number of prevalent cases of Acid sphingomyelinase deficiency (ASMD) in 10EM was found to be 8,799, in the year 2017.

Report Scope
  • The report covers detailed overview of Acid sphingomyelinase deficiency explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
  • The report provides the insight about the historical and forecasted patient pool of Acid sphingomyelinase deficiency in 10 emerging markets covering Turkey, Russia, Saudi Arabia, UAE, Mexico, Colombia, Brazil, Argentina, China and Taiwan. The Report assesses the disease risk and burden and highlights the unmet needs of the disease
  • The Report helps to recognize the growth opportunities in the 10EM with respect to the patient population
  • The report provides the segmentation of the disease epidemiology by total prevalent population, total diagnosed cases of Acid sphingomyelinase deficiency, diagnosed cases of ASMD by clinical phenotype, and diagnosed cases of ASMD based on clinical manifestations in 10EM
Key Strengths
  • 10 Year Forecast of Acid sphingomyelinase deficiency epidemiology
  • 10EM Coverage
  • Total Prevalent Cases of ASMDs
  • Prevalent Cases according to segmentation: total prevalent population, total diagnosed cases of Acid sphingomyelinase deficiency, diagnosed cases of ASMD by clinical phenotype, and diagnosed cases of ASMD based on clinical manifestations
Key Assessments
  • Patient Segmentation
  • Disease Risk & Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population
Note: Product cover images may vary from those shown
2 of 2
1. Key Insights

2. Acid sphingomyelinase deficiency Market Overview at a Glance
2.1. Market Share (%) Distribution of Acid sphingomyelinase deficiency in 2017
2.2. Market Share (%) Distribution of Acid sphingomyelinase deficiency in 2028

3. Disease Background and Overview
3.1. Introduction
3.2. History
3.3. Sub-types
3.3.1. NPD-A
3.3.2. NPD-B
3.4. Etiology of ASMD
3.5. Sign and Symptoms
3.6. Pathophysiology of ASMD
3.7. Diagnosis
3.7.1. Based on Chronic Visceral and Non-visceral ASMD
3.7.2. Based on Other Diseases
3.8. Biomarkers

4. Epidemiology and Patient Population - By Region
4.1. Key Findings
4.2. KOL Views

5. Ten Emerging Markets (EM) Total Prevalent Patient Population of Acid sphingomyelinase deficiency (ASMD)
5.1. Total Prevalence of Acid sphingomyelinase deficiency in 10 Emerging Markets
5.2. Diagnosed Prevalence of Acid sphingomyelinase deficiency in 10 Emerging Markets

6. Country Wise-Epidemiology of Acid sphingomyelinase deficiency (ASMD)
6.1. Emerging Markets: Assumptions and Rationale
6.2. China
6.2.1. Total Prevalent Cases of ASMD in China
6.2.2. Diagnosed Cases of ASMD in China
6.2.3. Diagnosed Cases of ASMD by clinical phenotype in China
6.2.4. Diagnosed Cases of ASMD based on clinical manifestations in China
6.3. Taiwan
6.3.1. Total Prevalent Cases of ASMD in Taiwan
6.3.2. Diagnosed Cases of ASMD in Taiwan
6.3.3. Diagnosed Cases of ASMD by clinical phenotype in Taiwan
6.3.4. Diagnosed Cases of ASMD based on clinical manifestations in Taiwan
6.4. Saudi Arabia
6.4.1. Total Prevalent Cases of ASMD in Saudi Arabia
6.4.2. Diagnosed Cases of ASMD in Saudi Arabia
6.4.3. Diagnosed Cases of ASMD by clinical phenotype in Saudi Arabia
6.4.4. Diagnosed Cases of ASMD based on clinical manifestations in Saudi Arabia
6.5. U.A.E.
6.5.1. Total Prevalent Cases of ASMD in UAE
6.5.2. Diagnosed Cases of ASMD in UAE
6.5.3. Diagnosed Cases of ASMD by clinical phenotype in UAE
6.5.4. Diagnosed Cases of ASMD based on clinical manifestations in UAE
6.6. Russia
6.6.1. Total Prevalent Cases of ASMD in Russia
6.6.2. Diagnosed Cases of ASMD in Russia
6.6.3. Diagnosed Cases of ASMD by clinical phenotype in Russia
6.6.4. Diagnosed Cases of ASMD based on clinical manifestations in Russia
6.7. Turkey
6.7.1. Total Prevalent Cases of ASMD in Turkey
6.7.2. Diagnosed Cases of ASMD in Turkey
6.7.3. Diagnosed Cases of ASMD by clinical phenotype in Turkey
6.7.4. Diagnosed Cases of ASMD based on clinical manifestations in Turkey
6.8. Mexico
6.8.1. Total Prevalent Cases of ASMD in Mexico
6.8.2. Diagnosed Cases of ASMD in Mexico
6.8.3. Diagnosed Cases of ASMD by clinical phenotype in Mexico
6.8.4. Diagnosed Cases of ASMD based on clinical manifestations in Mexico
6.9. Brazil
6.9.1. Total Prevalent Cases of ASMD in Brazil
6.9.2. Diagnosed Cases of ASMD in Brazil
6.9.3. Diagnosed Cases of ASMD by clinical phenotype in Brazil
6.9.4. Diagnosed Cases of ASMD based on clinical manifestations in Brazil
6.10. Argentina
6.10.1. Total Prevalent Cases of ASMD in Argentina
6.10.2. Diagnosed Cases of ASMD in Argentina
6.10.3. Diagnosed Cases of ASMD by clinical phenotype in Argentina
6.10.4. Diagnosed Cases of ASMD based on clinical manifestations in Argentina
6.11. Colombia
6.12. Total Prevalent Cases of ASMD in Colombia
6.13. Diagnosed Cases of ASMD in Colombia
6.14. Diagnosed Cases of ASMD by clinical phenotype in Colombia
6.15. Diagnosed Cases of ASMD based on clinical manifestations in Colombia

7. Appendix
7.1. Report Methodology

8. Capabilities

9. Disclaimer

10. About the Publisher
Note: Product cover images may vary from those shown
3 of 2

Loading
LOADING...

Adroll
adroll